Previous 10 | Next 10 |
Cellectar Biosciences ( CLRB -25.4% ) obliterates yesterday's 24% spike with its $10M direct stock offering to institutional investors. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Virtusa (NASDAQ: VRTU ) -24% on Q4 earnings . More news on: Virtusa Corporation, Cellectar Biosciences, Inc., EDAP TMS S.A., Stocks on the move, Read more ...
FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has entered into definitive a...
May 16, 2019 Palm Beach, FL –May 16, 2019 – The initial diagnosis and the 2 nd opinions all show that the global medical device markets are projected to have a very healthy revenue prognosis through 2014. In the 2018 edition of the EvaluateMedTech® ...
CLRB stock has been on a tear for the better part of the early hours of trading in Wednesday’s session after Cellectar Biosciences Inc (NASDAQ:CLRB) announced major positive news related to one of its flagship drugs. The drug in question is CLR131 and once the initial results of ...
Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...
Thinly traded nano cap Cellectar Biosciences ( CLRB +30.7% ) is up on a robust 32x surge in volume in reaction to preliminary data from Cohort 6 in its Phase 1 study of CLR 131 in patients with relapsed/refractory multiple myeloma. More news on: Cellectar Biosciences, Inc., Healthcare ...
Appliance Recycling Centers of America (NASDAQ: ARCI ) +19% on Q1 earnings . More news on: Appliance Recycling Centers of America, Inc., PDS Biotechnology Corporation, The Container Store Group, Inc., Stocks on the move, Read more ...
Results demonstrated 50% partial response rate, 50% minimal response rate, and 100% disease control rate Independent Data Monitoring Committee determines dose to be safe and well tolerated and recommends study continue to Cohort 7 FLORHAM PARK, N.J., May 15, 2019 (GLOBE NEWSWIRE) -...
Gainers: Cellectar Biosciences (NASDAQ: CLRB ) +7% . More news on: Cellectar Biosciences, Inc., INSYS Therapeutics, Inc., Soliton, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...